Xing Yan-Fang, Lin Jin-Xiang, Li Xing, Lin Qu, Ma Xiao-Kun, Chen Jie, Wu Dong-Hao, Wei Li, Yin Liang-Hong, Wu Xiang-Yuan
Department of Nephrology, First Affiliated Hospital of Jinan University, Guangzhou 510630, People's Republic of China.
School of Medicine, Jinan University, Guangzhou 510632, People's Republic of China.
Oncotarget. 2017 Jul 11;8(28):45391-45398. doi: 10.18632/oncotarget.17525.
Advance directives are a sensitive issue among traditional Chinese people, who usually refrain from mentioning this topic until it is imperative. Medical decisions for cancer patients are made by their families, and these decisions might violate patients' personal will.
This study aimed to examine the acceptance of advance directives among Chinese cancer patients and their families and patient participation in this procedure and, finally, to analyze the moral risk involved.
While 246 patients and their family members refused official discussion of an advance directive, the remaining 166 patients and their families accepted the concept of an advance directive and signed a document agreeing to give up invasive treatment when the anti-cancer treatment was terminated. Of these, only 24 patients participated in the decision making. For 101 patients, anti-cancer therapy was ended prematurely with as many as 37 patients not told about their potential loss of health interests.
Participants were 412 adult cancer patients from 9 leading hospitals across China. An advance directive was introduced to the main decision makers for each patient; if they wished to sign it, the advance directive would be systematically discussed. A questionnaire was given to the oncologists in charge of each patient to evaluate the interaction between families and patients, patients' awareness of their disease, and participation in an advance directive.
Advance directives were not widely accepted among Chinese cancer patients unless anti-cancer therapy was terminated. Most cancer patients were excluded from the discussion of an advance directive.
预立医疗指示在中国传统人群中是一个敏感问题,他们通常在迫不得已之前不会提及这个话题。癌症患者的医疗决策由其家人做出,而这些决策可能会违背患者的个人意愿。
本研究旨在调查中国癌症患者及其家属对预立医疗指示的接受程度以及患者在这一过程中的参与情况,并最终分析其中涉及的道德风险。
246名患者及其家属拒绝正式讨论预立医疗指示,其余166名患者及其家属接受了预立医疗指示的概念,并签署了一份文件,同意在抗癌治疗终止时放弃侵入性治疗。其中,只有24名患者参与了决策。对于101名患者,抗癌治疗被过早终止,多达37名患者未被告知其健康利益可能受损。
参与者为来自中国9家顶尖医院的412名成年癌症患者。向每位患者的主要决策者介绍预立医疗指示;如果他们愿意签署,将对预立医疗指示进行系统讨论。向负责每位患者的肿瘤学家发放问卷,以评估家属与患者之间的互动、患者对自身疾病的认知以及参与预立医疗指示的情况。
在中国癌症患者中,预立医疗指示并未被广泛接受,除非抗癌治疗终止。大多数癌症患者被排除在预立医疗指示的讨论之外。